Drug Profile
tICAM-1
Alternative Names: tICAM; tICAM-rhinovirus; tICAM453; truncated ICAM-1Latest Information Update: 09 Oct 2006
Price :
$50
*
At a glance
- Originator Bayer
- Class Antivirals
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 09 Oct 2006 Discontinued - Clinical-Phase-Unknown for Rhinovirus infections in USA (Intranasal)
- 16 May 2001 Profile reviewed but no significant changes made
- 16 May 2001 Investigation in Rhinovirus infections in USA (Intranasal)